{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:44:45Z","timestamp":1793061885429,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.cmi.2026.04.010","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:50:05Z","timestamp":1776408605000},"page":"1654-1661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetics, target attainment, and outcomes of piperacillin\/tazobactam in critically ill patients receiving continuous infusion with therapeutic drug monitoring: a retrospective analysis"],"prefix":"10.1016","volume":"32","author":[{"given":"Ute","family":"Chiriac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"M\u00fcnchow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anka C.","family":"R\u00f6hr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto R.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna T.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Frisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Gaasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus A.","family":"Weigand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian G.","family":"Wicha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Brinkmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2026.04.010_bib1","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2026.04.010_bib2","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.04.010_bib3","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1186\/s13054-020-03272-z","article-title":"Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT)","volume":"24","author":"Abdulla","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2026.04.010_bib4","doi-asserted-by":"crossref","first-page":"21891","DOI":"10.1038\/s41598-022-25967-9","article-title":"Low attainment to PK\/PD-targets for beta-lactams in a multi-center study on the first 72 h of treatment in ICU patients","volume":"12","author":"Smekal","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.cmi.2026.04.010_bib5","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/jama.2024.9779","article-title":"Continuous vs intermittent beta-lactam antibiotic infusions in critically ill patients with sepsis: the BLING III randomized clinical trial","volume":"332","author":"Dulhunty","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2026.04.010_bib6","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1001\/jama.2024.9803","article-title":"Prolonged vs intermittent infusions of beta-lactam antibiotics in adults with sepsis or septic shock: a systematic review and meta-analysis","volume":"332","author":"Abdul-Aziz","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2026.04.010_bib7","first-page":"1","article-title":"S3-Leitlinie Sepsis\u2013Pr\u00e4vention, Diagnose, Therapie und Nachsorge\u2013Update 2025","volume":"2","author":"Brunkhorst","year":"2025","journal-title":"Med Klin Intensivmed Notfmed"},{"key":"10.1016\/j.cmi.2026.04.010_bib8","doi-asserted-by":"crossref","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"49","author":"Evans","year":"2021","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2026.04.010_bib9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00134-021-06609-6","article-title":"Effect of therapeutic drug monitoring-based dose optimization of piperacillin\/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial","volume":"48","author":"Hagel","year":"2022","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2026.04.010_bib10","doi-asserted-by":"crossref","first-page":"101681","DOI":"10.1016\/j.xcrm.2024.101681","article-title":"Unraveling the impact of therapeutic drug monitoring via machine learning for patients with sepsis","volume":"5","author":"Ates","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.cmi.2026.04.010_bib11","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/cpt.2202","article-title":"From therapeutic drug monitoring to model-informed precision dosing for antibiotics","volume":"109","author":"Wicha","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cmi.2026.04.010_bib12","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.cmi.2023.03.018","article-title":"Individualized antimicrobial dose optimization: a systematic review and meta-analysis of randomized controlled trials","volume":"29","author":"Sanz-Codina","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.04.010_bib13","doi-asserted-by":"crossref","first-page":"1506109","DOI":"10.3389\/fphar.2025.1506109","article-title":"Economic impact of individualized antimicrobial dose optimization in the critically ill patient in Spain","volume":"16","author":"Grau","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cmi.2026.04.010_bib14","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000026253","article-title":"Personalized \u03b2-lactam dosing in patients with coronavirus disease 2019 (COVID-19) and pneumonia: a retrospective analysis on pharmacokinetics and pharmacokinetic target attainment","volume":"100","author":"Chiriac","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cmi.2026.04.010_bib15","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3390\/antibiotics10060667","article-title":"Personalized piperacillin dosing for the critically Ill: a retrospective analysis of clinical experience with dosing software and therapeutic drug monitoring to optimize antimicrobial dosing","volume":"10","author":"Chiriac","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2026.04.010_bib16","unstructured":"EUCAST. Breakpoints Piperacillin. Available online: http:\/\/www.eucast.org\/clinical_breakpoints (accessed on 09 December 2025).Eucast."},{"key":"10.1016\/j.cmi.2026.04.010_bib17","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s00063-018-0416-z","article-title":"[Dose adjustment of anti-infective drugs in patients with renal failure and renal replacement therapy in intensive care medicine: recommendations from the renal section of the DGIIN, OGIAIN and DIVI]","volume":"113","author":"Czock","year":"2018","journal-title":"Med Klin Intensivmed Notfmed"},{"key":"10.1016\/j.cmi.2026.04.010_bib18","unstructured":"Fresenius Kabi. Summary of Product Characteristics. Piperacillin\/Tazobactam Kabi 4 g\/0,5 g. Available online: https:\/\/www.fachinfo.de\/fi\/pdf\/011759 (accessed on 09 December 2025).SMPC, piperacillin."},{"key":"10.1016\/j.cmi.2026.04.010_bib19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00134-012-2769-8","article-title":"Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012","volume":"39","author":"Dellinger","year":"2013","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2026.04.010_bib20","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1007\/s00134-014-3403-8","article-title":"Risk factors for target non-attainment during empirical treatment with beta-lactam antibiotics in critically ill patients","volume":"40","author":"De Waele","year":"2014","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2026.04.010_bib21","doi-asserted-by":"crossref","first-page":"154904","DOI":"10.1016\/j.jcrc.2024.154904","article-title":"Target attainment of beta-lactam antibiotics and ciprofloxacin in critically ill patients and its association with 28-day mortality","volume":"85","author":"Dr\u00e4ger","year":"2025","journal-title":"J Crit Care"},{"key":"10.1016\/j.cmi.2026.04.010_bib22","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1007\/s00134-023-07154-0","article-title":"Towards model-informed precision dosing of piperacillin: multicenter systematic external evaluation of pharmacokinetic models in critically ill adults with a focus on Bayesian forecasting","volume":"49","author":"Greppmair","year":"2023","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2026.04.010_bib23","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1186\/s12879-022-07587-w","article-title":"Barriers and facilitators for therapeutic drug monitoring of beta-lactams and ciprofloxacin in the ICU: a nationwide cross-sectional study","volume":"22","author":"Ewoldt","year":"2022","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2026.04.010_bib24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/cid\/ciw709","article-title":"Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin-tazobactam compared to those on vancomycin and cefepime","volume":"64","author":"Navalkele","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.04.010_bib25","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1093\/jac\/dkx209","article-title":"Too much of a good thing: a retrospective study of beta-lactam concentration-toxicity relationships","volume":"72","author":"Imani","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.04.010_bib26","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1093\/jac\/dkad284","article-title":"Neurological burden and outcomes of excessive beta-lactam serum concentrations of critically ill septic patients: a prospective cohort study","volume":"78","author":"Zerbib","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.04.010_bib27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2215\/CJN.03681106","article-title":"Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes","volume":"2","author":"Bagshaw","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cmi.2026.04.010_bib28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJMoa0802639","article-title":"VA\/NIH Acute Renal Failure Trial Network, et al. Intensity of renal support in critically ill patients with acute kidney injury","volume":"359","author":"Palevsky","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.04.010_bib29","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1164\/rccm.201502-0329OC","article-title":"Acute kidney injury requiring dialysis in severe sepsis","volume":"192","author":"Sakhuja","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2026.04.010_bib30","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26001941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26001941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:10:44Z","timestamp":1790035844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X26001941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1198743X26001941"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2026.04.010","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics, target attainment, and outcomes of piperacillin\/tazobactam in critically ill patients receiving continuous infusion with therapeutic drug monitoring: a retrospective analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.05.025","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}